Treatment with AP1189 for patients with severe proteinuria due to idiopathic membranous nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an exploratory, randomized, double-blind, multicenter, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AP1189 in patients diagnosed with idiopathic membranous nephropathy (iMN) and severe proteinuria. Participants will be randomized into two groups, with one receiving AP1189 and the other a placebo, both as an add-on to their ongoing treatment with ACE inhibitors or angiotensin II receptor blockers. The study aims to assess the impact of AP1189 over a 12-week period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent has been obtained prior to initiating any study-specific procedures
* Male and female subjects, 18 to 85 years of age diagnosed with iMN within 6 months prior to inclusion
* Diagnosed as anti-PLA2-Receptor positive by local laboratory within 6 months prior to inclusion
* Severe proteinuria defined by a U-protein/creatinine ratio \>3.0 g/g and/or U-albumin/creatinine ratio \>2.0 g/g and a P-albumin below the lower normal limit
* eGFR \> 30 ml/min/1.73m2
* Treated with ACE- inhibitors or angiotensin II receptor blocker for a minimum of 1 months with a stable systemic arterial blood pressure OR treatment with ACE inhibitors and/or angiotensin receptor blocker was excluded or discontinued due to hypotension, intolerance or other side effect

Only Denmark and Norway:

* Females of child-bearing potential using reliable means of contraception or are post-menopausal
* Females of childbearing potential with negative pregnancy test at screening and baseline

Only Sweden:

* Post-menopausal women or women who are surgically sterilized.

Exclusion Criteria:

* Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry
* Clinicial findings that in the opinion of the investigator would suggest condition(s) other than iMN as a major cause of severe proteinuria
* Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization
* Blood pressure with systolic pressure above 160 mmHg and/or diastolic pressure above 100 mmHg despite antihypertensive treatment will in all cases be considered "uncontrolled"
* Treated with systemic corticosteroids, or other immune suppressive, or immune modulating compounds within 4 weeks prior to screening and during the entire treatment period and until the final visit
* Treated with rituximab within 12 months of screening
* Evidence of active malignant disease
* Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease
* Pregnant women or nursing mothers
* History of alcohol, drug, or chemical abuse within the 6 months prior to screening
* Any condition that in the view of the investigator would suggest that the patient is unable to comply with study protocol and procedures

Only Sweden:

* Females of child-bearing potential.

Where it's running

• Aarhus Universitetshospital
  Aarhus, Denmark Recruiting

Study contacts

• Principal investigator: Henrik Birn, Professor — Aarhus University Hospital
• Study coordinator: Irene Sandholdt
• Email: isa@croxxmed.com
• Phone: +45 2015 7033

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autoimmune podocytopathy and anti-nephrin antibodies

  This study tests whether children and adults with nephrotic syndrome have anti-nephrin autoantibodies and whether those antibodies relate to relapses and treatment response.

  Recruiting Meyer Children's Hospital IRCCS · Rochester, Minnesota and 13 other locations · NCT07516964

• Rivaroxaban to prevent blood clots in idiopathic membranous nephropathy

  This trial will test whether daily rivaroxaban prevents dangerous blood clots better than warfarin in adults with idiopathic membranous nephropathy who have nephrotic syndrome and very low albumin.

  Recruiting Phase 4 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07404436

• Huaier granule treatment for idiopathic membranous nephropathy

  This study is testing if Huaier granules can be a safe and effective treatment for people with idiopathic membranous nephropathy who haven't responded well to standard medications.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT05839314

• Comparing immunosuppressive treatments for idiopathic membranous nephropathy

  This study is testing two different treatments for idiopathic membranous nephropathy to see which one helps patients feel better and stay well longer.

  Recruiting Phase 3 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT04745728

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.